168 related articles for article (PubMed ID: 36521923)
21. Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis.
Wadström K; Jacobsson L; Mohammad AJ; Warrington KJ; Matteson EL; Turesson C
Rheumatology (Oxford); 2020 Nov; 59(11):3229-3236. PubMed ID: 32240313
[TBL] [Abstract][Full Text] [Related]
22. The Incidence and Predictors of Solid- and Hematological Malignancies in Patients with Giant Cell Arteritis: A Large Real-World Database Study.
Dar L; Ben-Shabat N; Tiosano S; Watad A; McGonagle D; Komaneshter D; Cohen A; Bragazzi NL; Amital H
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300046
[TBL] [Abstract][Full Text] [Related]
23. Risk of Cancer in 767 Patients with Giant Cell Arteritis in Western Norway: A Retrospective Cohort with Matched Controls.
Brekke LK; Fevang BS; Diamantopoulos AP; Assmus J; Esperø E; Gjesdal CG
J Rheumatol; 2020 May; 47(5):722-729. PubMed ID: 31308209
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period.
González-Gay MA; Garcia-Porrua C; Rivas MJ; Rodriguez-Ledo P; Llorca J
Ann Rheum Dis; 2001 Apr; 60(4):367-71. PubMed ID: 11247867
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data.
Mahr A; Belhassen M; Paccalin M; Devauchelle-Pensec V; Nolin M; Gandon S; Idier I; Hachulla E
Rheumatology (Oxford); 2020 Jan; 59(1):120-128. PubMed ID: 31382293
[TBL] [Abstract][Full Text] [Related]
26. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009.
Chandran AK; Udayakumar PD; Crowson CS; Warrington KJ; Matteson EL
Scand J Rheumatol; 2015 May; 44(3):215-8. PubMed ID: 25606666
[TBL] [Abstract][Full Text] [Related]
27. Statin use in giant cell arteritis: a retrospective study.
Schmidt J; Kermani TA; Muratore F; Crowson CS; Matteson EL; Warrington KJ
J Rheumatol; 2013 Jun; 40(6):910-5. PubMed ID: 23547221
[TBL] [Abstract][Full Text] [Related]
28. Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.
Brekke LK; Fevang BS; Diamantopoulos AP; Assmus J; Esperø E; Gjesdal CG
Arthritis Res Ther; 2019 Jun; 21(1):154. PubMed ID: 31238961
[TBL] [Abstract][Full Text] [Related]
29. Infections and the risk of incident giant cell arteritis: a population-based, case-control study.
Rhee RL; Grayson PC; Merkel PA; Tomasson G
Ann Rheum Dis; 2017 Jun; 76(6):1031-1035. PubMed ID: 27895041
[TBL] [Abstract][Full Text] [Related]
30. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
Crowson CS; Matteson EL
Semin Arthritis Rheum; 2017 Oct; 47(2):253-256. PubMed ID: 28551169
[TBL] [Abstract][Full Text] [Related]
31. Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study.
Muratore F; Boiardi L; Mancuso P; Restuccia G; Galli E; Marvisi C; Macchioni P; Rossi PG; Salvarani C
Semin Arthritis Rheum; 2021 Aug; 51(4):786-792. PubMed ID: 34148007
[TBL] [Abstract][Full Text] [Related]
32. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
33. Giant cell arteritis in Lugo, Spain: a more frequent disease with fewer classic features.
González-Gay MA; Blanco R; Sánchez-Andrade A; Vázquez-Caruncho M
J Rheumatol; 1997 Nov; 24(11):2166-70. PubMed ID: 9375879
[TBL] [Abstract][Full Text] [Related]
34. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study.
Aviña-Zubieta JA; Bhole VM; Amiri N; Sayre EC; Choi HK
Ann Rheum Dis; 2016 Jan; 75(1):148-54. PubMed ID: 25265937
[TBL] [Abstract][Full Text] [Related]
35. The incidence of giant cell arteritis in Slovenia.
Pucelj NP; Hočevar A; Ješe R; Rotar Ž; Hawlina M; Fakin A; Pižem J; Tomšič M
Clin Rheumatol; 2019 Feb; 38(2):285-290. PubMed ID: 30062445
[TBL] [Abstract][Full Text] [Related]
36. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.
Kermani TA; Warrington KJ; Crowson CS; Ytterberg SR; Hunder GG; Gabriel SE; Matteson EL
Ann Rheum Dis; 2013 Dec; 72(12):1989-94. PubMed ID: 23253927
[TBL] [Abstract][Full Text] [Related]
37. Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.
Koster MJ; Achenbach SJ; Crowson CS; Maradit-Kremers H; Matteson EL; Warrington KJ
J Rheumatol; 2017 Jul; 44(7):1044-1050. PubMed ID: 28461641
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis.
Chen JJ; Leavitt JA; Fang C; Crowson CS; Matteson EL; Warrington KJ
Ophthalmology; 2016 Sep; 123(9):1999-2003. PubMed ID: 27297405
[TBL] [Abstract][Full Text] [Related]
39. Giant cell arteritis and mortality.
Crow RW; Katz BJ; Warner JE; Alder SC; Zhang K; Schulman S; Digre KB
J Gerontol A Biol Sci Med Sci; 2009 Mar; 64(3):365-9. PubMed ID: 19196636
[TBL] [Abstract][Full Text] [Related]
40. Body mass index and the risk of giant cell arteritis: results from a prospective study.
Jakobsson K; Jacobsson L; Warrington K; Matteson EL; Liang K; Melander O; Turesson C
Rheumatology (Oxford); 2015 Mar; 54(3):433-40. PubMed ID: 25193806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
